EGFR, epidermal growth factor receptor, 1956

N. diseases: 1394; N. variants: 183
Disease: Glioblastoma Multiforme ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE However, EGFR amplification is poorly represented in glioblastoma cell lines. 30509096 2019
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 GeneticVariation disease BEFREE Copy number amplification of the epidermal growth factor receptor gene occurs in intermediate and late-stage tumors whereas loss of heterozygosity for loci on chromosome 10 is restricted to the ultimate stage, glioblastoma multiforme. 2011137 1991
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE Additionally, such gains or amplifications were present in all tumor samples where the initial histopathological diagnosis was glioblastoma and immunohistochemical study disclosed p53 tumor suppressor protein negative and epidermal growth factor receptor positive immunoreactivity; such glioblastomas possessing p53 tumor suppressor protein positive and epidermal growth factor receptor negative immunoreactivity seldom displayed any gain. 10982006 2000
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 GeneticVariation disease BEFREE Epidermal growth factor receptor variant III (EGFRvIII) is a cancer-specific deletion mutant observed in approximately 25% to 50% of glioblastoma multiforme (GBM) patients. 25931519 2015
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. 28629170 2017
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE Flow cytometry demonstrated increased apoptosis in C225-treated, EGFR-amplified GBM lines, but not in unamplified lines. 12234411 2002
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE We found amplification of the EGFR gene in 49% (18/37) of GBM but not in the astrocytomas WHO II/III. 7760096 1994
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 AlteredExpression disease BEFREE Endogenous expressions of EGFR in various GBM cells were determined by western blotting. 25886314 2015
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 AlteredExpression disease BEFREE Thus, PDGX with high EGFR activity represent an excellent pre-clinical model to develop therapies for a subset of GBM patients whose tumors are characterized by high EGFR activity. 25598002 2015
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 AlteredExpression disease BEFREE We further validate the method with glioblastoma and leukemia sample data and then apply it to complex integrated genomics databases, finding that high-level EGFR amplification appears to be a late event in primary glioblastomas. 20864632 2010
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE These findings support intracranial administration of NK-92-EGFR-CAR cells represents a promising clinical strategy to treat GB. 26155832 2015
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. 20532243 2010
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE Here, we describe recent knowledge on the signaling pathways mediated by EGFR/EGFR variant III (EGFRvIII) with regard to current therapeutic strategies to target EGFR/EGFRvIII amplified glioblastoma. 31013819 2019
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 GeneticVariation disease BEFREE Locus amplification, gene overexpression, and genetic mutations of epidermal growth factor receptor (EGFR) are hallmarks of GBM that can ectopically activate downstream signaling oncogenic cascades such as PI3K/Akt/mTOR pathway. 24691646 2014
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE Phosphorylation of Y240 is associated with shortened overall survival and resistance to EGFR inhibitor therapy in GBM patients and plays an active role in mediating resistance to EGFR inhibition in vitro. 22891331 2012
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE For this purpose, immunophenotyping was performed to study the simultaneous expression of p53 protein and epidermal growth factor receptor (EGFR) in 58 cases of adult supratentorial GBM. 15696962 2004
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 GeneticVariation disease BEFREE In this study we determined whether EGFR amplification and expression of the most common mutation in GBMs (EGFRvIII) is retained at tumor recurrence. 25691693 2015
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE The tumoricidal and TMZ-sensitizing effects of BI2536 were uniformly observed across Ink4a/Arf(-/-) EGFRvIII glioblastoma clones that acquired independent resistance mechanisms to EGFR inhibitors, suggesting these resistant clones retain oncogenic stress that required PLK1 compensation. 26059434 2015
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE The cell lines showed frequent SNVs and indels in some of the genes that are known to be altered in GBM- EGFR, TP53, PTEN, SPTA1 and NF1. 26496030 2015
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 AlteredExpression disease BEFREE We have previously shown that differential expression of the epidermal growth factor receptor in glioblastoma cells affects PpIX fluorescence. 31734545 2019
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE A link between the uPA-uPAR-ERK1/2 pathway and BIM has not been previously demonstrated in GBM, and involvement of this signaling axis in resistance provides rationale for a new strategy to target EGFR TKI-resistant GBM. 25432173 2015
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE To assess the dependence of EGFR inhibited phenotype on p53, we used three mutant p53 glioblastoma cell lines in the present study and showed that mutant erbB2 can be exploited to inhibit EGFR-mediated oncogenic transformation irrespective of p53 status. 17457042 2007
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE COX-2 is also regulated by epidermal growth factor receptor signaling which is important in the pathogenesis of GBMs. 24659686 2014
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 AlteredExpression disease BEFREE In this study we have examined the epidermal growth factor receptor gene (EGFR) region for the amplification of novel expressed sequences in 28 glioblastoma tumors and two cell lines with EGFR gene amplification. 9464536 1998
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.500 Biomarker disease BEFREE Downregulation of NHE9 expression by miR-135a acidifies sorting endosomes limiting EGFR trafficking to the glioblastoma cell membrane. 29268774 2017